Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients

MT Newswires Live05-28

Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.

The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.

Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.

Shares of Altimmune rose more than 3% in Thursday trading.

Price: 3.07, Change: +0.09, Percent Change: +3.15

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2638927836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638927836","market":"us","top_or_hot":-1,"title":"Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients","media":"MT Newswires Live","content":"<html><body><p> Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.</p><p>The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.</p><p>The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.</p><p>Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.</p><p>Shares of Altimmune rose more than 3% in Thursday trading.</p><p>Price: 3.07, Change: +0.09, Percent Change: +3.15</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-28 23:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.</p><p>The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.</p><p>The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.</p><p>Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.</p><p>Shares of Altimmune rose more than 3% in Thursday trading.</p><p>Price: 3.07, Change: +0.09, Percent Change: +3.15</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALT","symbol_name":"Altimmune, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638927836","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638927836","pubTimestamp":1779983663,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Altimmune  said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.Shares of Altimmune rose more than 3% in Thursday trading.Price: 3.07, Change: +0.09, Percent Change: +3.15","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALT":"Altimmune, Inc.","BK4599":"减肥药","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","BK4139":"生物科技"},"translate_title":"Altimmune表示Pemvidutide数据显示MASH患者的代谢改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALT":1},"content_text":"Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.Shares of Altimmune rose more than 3% in Thursday trading.Price: 3.07, Change: +0.09, Percent Change: +3.15","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2638927836","isCrawlerRequest":true}